NCR1 and acute myeloid leukemia: On the other hand, co-treatment with the STAT3 signaling pathway inhibitor S3I-201 and 0.4 umol/L decitabine for 24 h had a dramatic cytotoxicity-enhancing influence on AML-NK cells (Figure 5C), and resulted in markedly increased expression levels of NKp46 and NKG2D (Figures 5D,E).